Myriad Genetics Partners with SOPHiA GENETICS for Innovative Liquid Biopsy Companion Diagnostics

Myriad Genetics and SOPHiA GENETICS Forge Strategic Alliance for Liquid Biopsy Companion Diagnostics

Myriad Genetics, a prominent player in molecular diagnostic testing, has initiated a strategic collaboration with SOPHiA GENETICS, an AI technology company. This partnership is poised to develop a global liquid biopsy companion diagnostic (CDx) test tailored for pharmaceutical companies. The collaboration leverages Myriad's sophisticated laboratory capabilities in the United States alongside SOPHiA's expansive network of over 800 connected institutions in more than 70 countries. This synergy aims to facilitate the global deployment of innovative diagnostic solutions, ultimately enhancing the patient experience within the cancer care continuum.

At the forefront of this initiative is the development of the MSK-ACCESS® test, powered by SOPHiA DDM™. This advanced liquid biopsy application is designed to detect actionable genomic alterations from a single blood draw, utilizing sophisticated algorithms to analyze circulating tumor DNA (ctDNA). Sam Raha, President and CEO of Myriad Genetics, underscores that the collaboration focuses on enhancing comprehensive CDx solutions to support Biopharma partners. By streamlining the diagnostic process, the partnership not only aims to improve patient outcomes but also positions Myriad for growth in its CDx programs, a crucial segment of the oncology diagnostics market.

Regulatory responsibilities for the new test are divided, with Myriad overseeing submissions in the U.S. and SOPHiA managing international regulations. This collaborative approach signifies a significant shift in the industry, as articulated by Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. The partnership combines the strengths of Myriad’s specialty lab capabilities with SOPHiA’s global testing network, thereby enhancing access to cutting-edge oncology testing solutions. Both companies plan to share insights about their collaboration during a panel discussion at the World CB and CDx Summit in Boston, highlighting the transformative potential of their work in advancing personalized healthcare through innovative liquid biopsy solutions.

In related news, Myriad Genetics continues to enhance its portfolio by focusing on precision medicine, which is increasingly becoming the standard in cancer treatment and diagnosis. The collaboration with SOPHiA marks a pivotal moment in the evolution of companion diagnostics, as it emphasizes the importance of integrating advanced technologies in the pursuit of better patient care.

The advancements in liquid biopsy technology not only promise to improve diagnostic accuracy but also aim to reduce the burden on patients by providing a less invasive testing option. This strategic alliance is expected to set new benchmarks in the field of oncology diagnostics, further solidifying Myriad Genetics’ role as a leader in the industry.